Other mechanisms of accumulation of 188Re-based therapies worth mentioning are the use of rhenium-188 as a substrate for the sodium/iodine symporter (NIS) and the development of a tumour microenvironment targeting radiopharmaceuticals. Here, SLC5A5 is linked to neoplasm.